Novavax's COVID-19 Vaccine Scores Green Light In India with First Approval For Adolescents - Novavax (NASDAQ:NVAX)

Novavax Inc's NVAX COVID-19 vaccine has got emergency-use authorization from the Drugs Controller General of India for children aged 12 to 17 years.
The authorization is a global first approval in adolescents for the vaccine manufactured and marketed in India by the Serum Institute of India under the brand name Covovax.
Novavax said its vaccine was 80% effective against COVID-19 in a late-stage trial testing the shot in 2,247 teens aged 12 to 17 years.
The company said its vaccine produced an immune response in the same age group in a mid-to-late-stage study involving 460 Indian adolescents.
Related: Novavax's COVID-19 Shot Inches Up To FDA Authorization: WSJ.
Covovax is the fourth COVID-19 vaccine authorized for adolescents aged 12 years and older in India after Biological E's Corbevax, Zydus Cadila's ZyCoV-D, and Bharat Biotech's Covaxin.
India, which had been vaccinating children aged 15 and above, started administering doses of Biological E's Corbevax last week to children aged 12 to 14.
Price Action: NVAX shares are down 0.60% at $83.30 during the premarket session on the last check Wednesday.